Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative pain, anxiety, and depression after tumor surgery
ChiCTR2600134658Phase 4Completed
- Sponsor
- Huzhou Central Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in postoperative pain, anxiety disorder and major depressive disorder (MDD) (3 arms), sponsored by Huzhou Central Hospital. Primary endpoint: Incidence of moderate-to-severe postoperative pain. Started Jan 2022; status: completed.
02
Drugs
esketamine
03
Conditions
postoperative painanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600134658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134658.